Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Capital Employed (2016 - 2025)

Zevra Therapeutics' Return on Capital Employed history spans 10 years, with the latest figure at 0.26% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 31.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, up 31.0%, while the annual FY2025 figure was 0.33%, 29.0% up from the prior year.
  • Return on Capital Employed reached 0.26% in Q4 2025 per ZVRA's latest filing, up from 0.37% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.55% in Q3 2022 to a low of 0.65% in Q3 2024.
  • Average Return on Capital Employed over 5 years is 0.23%, with a median of 0.26% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: soared 159bps in 2021, then plummeted -31bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.06% in 2021, then crashed by -516bps to 0.25% in 2022, then plummeted by -31bps to 0.32% in 2023, then plummeted by -79bps to 0.58% in 2024, then skyrocketed by 54bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Return on Capital Employed are 0.26% (Q4 2025), 0.37% (Q3 2025), and 0.64% (Q2 2025).